BioStock: Ultimovacs enters next step in new vaccine platform development

Report this content
Ultimovacs’ TENDU trial is a clinical phase I study aimed at testing the company’s TET platform for cancer vaccine development in prostate cancer patients. The study was initiated earlier this year with the first cohort of patients; now the company has announced dosing the first patient in the second of three cohorts for the TENDU study.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/10/ultimovacs-enters-next-step-in-new-vaccine-platform-development-2/

This is a press release from BioStock - Connecting Innovation & Capital.

Subscribe

Documents & Links

Quick facts

BioStock: Ultimovacs enters next step in new vaccine platform development
Tweet this